Fulcrum Therapeutics ( (FULC) ) has released its Q2 earnings. Here is a breakdown of the information Fulcrum Therapeutics presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Fulcrum Therapeutics, Inc., a biotechnology company based in Cambridge, Massachusetts, focuses on developing small molecules for genetically-defined rare diseases with high unmet medical needs. In its latest earnings report for the quarter ended June 30, 2025, Fulcrum Therapeutics reported a net loss of $17.3 million, a significant shift from the $55.4 million net income in the same period last year, primarily due to the absence of collaboration revenue. The company’s operating expenses decreased to $19.8 million from $27.5 million, reflecting a reduction in research and development as well as general and administrative costs. Despite the financial loss, Fulcrum maintains a strong cash position with $42.6 million in cash and cash equivalents and $171.5 million in marketable securities, which the company believes will fund its operations for at least the next 12 months. Looking forward, Fulcrum Therapeutics remains committed to advancing its clinical trials and research programs, with a focus on its lead product candidate, pociredir, and exploring strategic opportunities to enhance its pipeline and financial standing.